Amgen and Allergan have obtained marketing authorisation from the European Commission (EC) for biosimilar MVASI to treat select cancer types in the European Union (EU).

MVASI is a biosimilar to bevacizumab, a recombinant immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to vascular endothelial growth factor (VEGF).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Bevacizumab blocks the interaction between VEGF and its receptors to inhibit the formation of new blood vessels required by solid tumours for their maintenance and growth.

The EC authorisation indicates the use of MVASI in combination with various other anticancer therapies for metastatic carcinoma of the colon or rectum, breast cancer, renal cell cancer and unresectable advanced non-squamous non-small cell lung cancer (NSCLC).

“MVASI is the first targeted cancer biosimilar from Amgen’s portfolio approved in Europe, underscoring our commitment to delivering high-quality medicines that address some of the most serious illnesses.”

The permit also covers the treatment of advanced, platinum-sensitive, or platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer; and persistent, recurrent or metastatic cervix carcinoma.

Amgen research and development executive vice-president Sean Harper said: “The European Commission’s approval of MVASI marks a significant milestone for both Amgen and the oncology community, providing a biosimilar for a medicine which is used across multiple types of cancer.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“MVASI is the first targeted cancer biosimilar from Amgen’s portfolio approved in Europe, underscoring our commitment to delivering high-quality medicines that address some of the most serious illnesses.”

Prior to the approval, the EC reviewed a comprehensive data package that reportedly demonstrated the similarity between MVASI and bevacizumab.

The agency did not find any clinically meaningful differences in the efficacy, safety and immunogenicity of the products.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact